BCMA ANTIGEN BINDING PROTEINS

摘要

The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.

主权项

1. An isolated monoclonal antibody, or BCMA-binding fragment thereof, selected from the group consisting of:
an antibody comprising a Vh-CDR1 comprising SEQ ID NO:4, a Vh-CDR2 comprising SEQ ID NO:5, a Vh-CDR3 comprising SEQ ID NO:6, a Vl-CDR1 comprising SEQ ID NO:106, a Vl-CDR2 comprising SEQ ID NO:107, and a Vl-CDR3 comprising SEQ ID NO:108; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:10, a Vh-CDR2 comprising SEQ ID NO:11, a Vh-CDR3 comprising SEQ ID NO:12, a Vl-CDR1 comprising SEQ ID NO:112, a Vl-CDR2 comprising SEQ ID NO:113, and a Vl-CDR3 comprising SEQ ID NO:114; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:16, a Vh-CDR2 comprising SEQ ID NO:17, a Vh-CDR3 comprising SEQ ID NO:18, a Vl-CDR1 comprising SEQ ID NO:118, a Vl-CDR2 comprising SEQ ID NO:119, and a Vl-CDR3 comprising SEQ ID NO:120; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:22, a Vh-CDR2 comprising SEQ ID NO:23, a Vh-CDR3 comprising SEQ ID NO:24, a Vl-CDR1 comprising SEQ ID NO:124, a Vl-CDR2 comprising SEQ ID NO:125, and a Vl-CDR3 comprising SEQ ID NO:126; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:28, a Vh-CDR2 comprising SEQ ID NO:29, a Vh-CDR3 comprising SEQ ID NO:30, a Vl-CDR1 comprising SEQ ID NO:130, a Vl-CDR2 comprising SEQ ID NO:131, and a Vl-CDR3 comprising SEQ ID NO:132; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:34, a Vh-CDR2 comprising SEQ ID NO:35, a Vh-CDR3 comprising SEQ ID NO:36, a Vl-CDR1 comprising SEQ ID NO:136, a Vl-CDR2 comprising SEQ ID NO:137, and a Vl-CDR3 comprising SEQ ID NO:138; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:40, a Vh-CDR2 comprising SEQ ID NO:41, a Vh-CDR3 comprising SEQ ID NO:42, a Vl-CDR1 comprising SEQ ID NO:142, a Vl-CDR2 comprising SEQ ID NO:143, and a Vl-CDR3 comprising SEQ ID NO:144; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:46, a Vh-CDR2 comprising SEQ ID NO:47, a Vh-CDR3 comprising SEQ ID NO:48, a Vl-CDR1 comprising SEQ ID NO:148, a Vl-CDR2 comprising SEQ ID NO:149, and a Vl-CDR3 comprising SEQ ID NO:150; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:52, a Vh-CDR2 comprising SEQ ID NO:53, a Vh-CDR3 comprising SEQ ID NO:54, a Vl-CDR1 comprising SEQ ID NO:154, a Vl-CDR2 comprising SEQ ID NO:155, and a Vl-CDR3 comprising SEQ ID NO:156; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:58, a Vh-CDR2 comprising SEQ ID NO:59, a Vh-CDR3 comprising SEQ ID NO:60, a Vl-CDR1 comprising SEQ ID NO:160, a Vl-CDR2 comprising SEQ ID NO:161, and a Vl-CDR3 comprising SEQ ID NO:162; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:64, a Vh-CDR2 comprising SEQ ID NO:65, a Vh-CDR3 comprising SEQ ID NO:66, a Vl-CDR1 comprising SEQ ID NO:166, a Vl-CDR2 comprising SEQ ID NO:167, and a Vl-CDR3 comprising SEQ ID NO:168; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:70, a Vh-CDR2 comprising SEQ ID NO:71, a Vh-CDR3 comprising SEQ ID NO:72, a Vl-CDR1 comprising SEQ ID NO:172, a Vl-CDR2 comprising SEQ ID NO:173, and a Vl-CDR3 comprising SEQ ID NO:174; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:76, a Vh-CDR2 comprising SEQ ID NO:77, a Vh-CDR3 comprising SEQ ID NO:78, a Vl-CDR1 comprising SEQ ID NO:178, a Vl-CDR2 comprising SEQ ID NO:179, and a Vl-CDR3 comprising SEQ ID NO:180; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:82, a Vh-CDR2 comprising SEQ ID NO:83, a Vh-CDR3 comprising SEQ ID NO:84, a Vl-CDR1 comprising SEQ ID NO:184, a Vl-CDR2 comprising SEQ ID NO:185, and a Vl-CDR3 comprising SEQ ID NO:186; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:88, a Vh-CDR2 comprising SEQ ID NO:89, a Vh-CDR3 comprising SEQ ID NO:90, a Vl-CDR1 comprising SEQ ID NO:190, a Vl-CDR2 comprising SEQ ID NO:191, and a Vl-CDR3 comprising SEQ ID NO:192; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:94, a Vh-CDR2 comprising SEQ ID NO:95, a Vh-CDR3 comprising SEQ ID NO:96, a Vl-CDR1 comprising SEQ ID NO:196, a Vl-CDR2 comprising SEQ ID NO:197, and a Vl-CDR3 comprising SEQ ID NO:198; an antibody comprising a Vh-CDR1 comprising SEQ ID NO:100, a Vh-CDR2 comprising SEQ ID NO:101, a Vh-CDR3 comprising SEQ ID NO:102, a Vl-CDR1 comprising SEQ ID NO:202, a Vl-CDR2 comprising SEQ ID NO:203, and a Vl-CDR3 comprising SEQ ID NO:204; an Ab-1Vl domain comprising SEQ ID NO:240 and an Ab-1Vh domain comprising SEQ ID NO:206; an Ab-2Vl domain comprising SEQ ID NO:242 and an Ab-2Vh domain comprising SEQ ID NO:208; an Ab-3Vl domain comprising SEQ ID NO:244 and an Ab-3Vh domain comprising SEQ ID NO:210; an Ab-4Vl domain comprising SEQ ID NO:246 and an Ab-4Vh domain comprising SEQ ID NO:212; an Ab-5Vl domain comprising SEQ ID NO:248 and an Ab-5Vh domain comprising SEQ ID NO:214; an Ab-6Vl domain comprising SEQ ID NO:250 and an Ab-6Vh domain comprising SEQ ID NO:216; an Ab-7Vl domain comprising SEQ ID NO:252 and an Ab-7Vh domain comprising SEQ ID NO:218; an Ab-8Vl domain comprising SEQ ID NO:254 and an Ab-8Vh domain comprising SEQ ID NO:220; an Ab-9Vl domain comprising SEQ ID NO:256 and an Ab-9Vh domain comprising SEQ ID NO:222; an Ab-10Vl domain comprising SEQ ID NO:258 and an Ab-10Vh domain comprising SEQ ID NO:224; an Ab-11Vl domain comprising SEQ ID NO:260 and an Ab-11Vh domain comprising SEQ ID NO:226; an Ab-12Vl domain comprising SEQ ID NO:262 and an Ab-12Vh domain comprising SEQ ID NO:228; an Ab-13Vl domain comprising SEQ ID NO:264 and an Ab-13Vh domain comprising SEQ ID NO:230; an Ab-14Vl domain comprising SEQ ID NO:266 and an Ab-14Vh domain comprising SEQ ID NO:232; an Ab-15Vl domain comprising SEQ ID NO:268 and an Ab-15Vh domain comprising SEQ ID NO:234; an Ab-16Vl domain comprising SEQ ID NO:270 and an Ab-16Vh domain comprising SEQ ID NO:236; an Ab-17Vl domain comprising SEQ ID NO:272 and an Ab-17Vh domain comprising SEQ ID NO:238); an Ab-1 light chain comprising SEQ ID NO:280 and an Ab-1 heavy chain comprising SEQ ID NO:274; an Ab-2 light chain comprising SEQ ID NO:282 and an Ab-2 heavy chain comprising SEQ ID NO:276; and an Ab-3 light chain comprising SEQ ID NO:284 and an Ab-3 heavy chain comprising SEQ ID NO:278,wherein said antibody or fragment thereof specifically binds human BCMA.